Andhra Pradesh - Visakhapatnam   

GITAM, Japan-based pharma firm sign MoU

VISAKHAPATNAM: GITAM University and a Japan-based pharmaceutical company, Eisai Pharmatechnology and Manufacturing Private Ltd., have entered into an MoU to take up joint research programmes for better health care.

As part of the agreement, the Japanese company will provide need-based support in establishing an industrial pilot plant in GITAM Institute of Pharmacy towards R&D and also help GITAM University in designing, delivering and periodic updating of curriculum for B.Pharm. and M. Pharm programmes to meet the pharma industry needs.

The MoU will promote cooperation and advancement of industry-university interaction and Eisai will support research in its areas of excellence like neurology, gastrointestinal disorders, oncology and acute care, according to a GITAM University press release.

The MoU was signed on Thursday by Eisai president S.S. Lamba and GITAM University Registrar M. Potha Raju in the presence of Vice-Chancellor G. Subramanyam, Pro Vice-Chancellor D. Harinarayana, Eisai Knowledge Centre HR and Administration Director S.R. Saini. and GITAM Institute of Pharmacy principal P. Suresh.

Drug research

Mr. Lamba said that his organisation would extend its support to GITAM University to train quality human resources. Eisai was actively involved in new drug research and a few new anticancer drugs were in the final stage.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Fevers on the rise in Agency
Long wait for opening of archaeology museum
GITAM, Japan-based pharma firm sign MoU
AU Regional PG CET admissions on
Counselling for MBA aspirants today
15 more fire stations to come up in the city
Woman robbed of gold chain
Yoga classes for children
‘Aalankrita' brochure released
Maharashtra civic official meets Vishnu
DJ Aqeel to rock The Park
“She's a jolly good fellow” release today
In Visakhapatnam Today

Copyright © 2010, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu